Promedior Inc., today announced positive data from Stage 1 of an adaptive two-stage Phase 2 trial of PRM-151, a novel anti-fibrotic immunotherapy, in patients with myelofibrosis. The overall response rate (ORR), defined as IWG-MRT1 (International Working Group-Myeloproliferative Neoplasms Research and Treatment) responses or reduction in bone marrow fibrosis, was 43 percent at 6 months, surpassing the pre-specified efficacy criteria necessary to proceed to the next stage of Promedior’s Phase 2 trial. Data presented at the American Society of Hematology (ASH) meeting demonstrate reduction of bone marrow fibrosis by at least one grade observed in 42 percent of patients which was associated in most patients with improvements in anemia and/or thrombocytopenia and, in some patients, by transfusion independence lasting at least 24 weeks. Bone marrow fibrosis grade is correlated with anemia, thrombocytopenia, peripheral blasts and shortened survival2,3. These study results were presented in an oral presentation by principal investigator Srdan Verstovsek, MD, PhD, at the ASH 2014 Annual Meeting on December 8, 2014.